Stockreport

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSenseCAMBRIDGE, Mass., April 4, 202 [Read more]